( MENAFN - PR Newswire) Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif., Oct. 29, 2024 /PRNewswire/ -- Nevro Corp.
(NYSE: NVRO ), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (PDN) and Type 2 diabetes who received 10 kHz high-frequency spinal cord stimulation (SCS) therapy.1 Globally, the number of people with diabetes has quadrupled in the last two decades2, and PDN impacts up to 25% of all people with diabetes.3 PDN can have significant impacts on the quality of life for people living with this condition, with symptoms like numbness, tingling/paresthesia, loss of protective sensation, impaired balance, and reduced response to sensory stimuli.
4 Patients typically manage PDN with oral pain medications, but the efficacy of these medications is relatively low and can result in intolerable side effects.5 As a result, people with PDN suffer from significantly reduced health-related quality of life (HRQoL), impaired functionality and other com.
